CAMBRIDGE, Mass.--(BUSINESS WIRE)--PixarBio Corporation announced today the appointment of Taunia Markvicka as Chief Commercial Officer (CCO). Taunia joins PixarBio from Pacira Pharmaceuticals where she was Chief Commercial Officer responsible for US sales of post-op pain drug Exparel.
Taunia will report to Frank Reynolds, the company’s founder and Chief Executive Officer. Taunia is another important piece to the company’s growing leadership infrastructure, and in maintaining momentum toward commercialization of NeuroRelease, PixarBio’s non-opiate and non-addictive pain treatments with expected FDA approvals in 2018.
